Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Neuroendocrine tumor disease: an evolving landscape.

Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM.

Endocr Relat Cancer. 2012 Sep 14;19(5):R163-85. doi: 10.1530/ERC-12-0024. Print 2012 Oct. Review.

2.

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP.

Gastroenterology. 2010 Sep;139(3):742-53, 753.e1. doi: 10.1053/j.gastro.2010.07.002. Epub 2010 Jul 13. Review.

PMID:
20637207
3.

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM.

Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii. doi: 10.1016/j.ecl.2010.12.001. Review.

PMID:
21349414
4.

Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

Alexandraki KI, Kaltsas G.

Endocrine. 2012 Feb;41(1):40-52. doi: 10.1007/s12020-011-9562-2. Epub 2011 Nov 29. Review.

PMID:
22124940
5.

Neuroendocrine neoplasms of the gastrointestinal tract.

Schott M, Klöppel G, Raffel A, Saleh A, Knoefel WT, Scherbaum WA.

Dtsch Arztebl Int. 2011 May;108(18):305-12. doi: 10.3238/arztebl.2011.0305. Epub 2011 May 6. Review.

6.

Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.

Lindholm DP, Oberg K.

Horm Metab Res. 2011 Nov;43(12):832-7. doi: 10.1055/s-0031-1287794. Epub 2011 Oct 18. Review.

PMID:
22009449
7.

Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.

Singh S, Law C.

Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):313-34. doi: 10.1586/egh.12.15. Review.

PMID:
22646254
8.

Systemic treatment of neuroendocrine tumors with hepatic metastases.

Demirkan BH, Eriksson B.

Turk J Gastroenterol. 2012;23(5):427-37. Review.

9.

[The somatostatin receptor family--a window against new diagnosis and therapy of cancer].

Hofsli E.

Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):487-91. Review. Norwegian.

PMID:
11961977
10.

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.

Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki MJ, Oberg K, Knigge U.

Acta Oncol. 2010 Aug;49(6):740-56. doi: 10.3109/0284186X.2010.492791. Review.

PMID:
20553100
11.

[Neuroendocrine tumours of pancreas and gastrointestinal tract].

Tsimmerman IaS.

Klin Med (Mosk). 2009;87(12):7-13. Review. Russian.

PMID:
20135878
12.

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.

Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M.

Langenbecks Arch Surg. 2011 Dec;396(8):1145-56. doi: 10.1007/s00423-011-0794-7. Epub 2011 Apr 27. Review.

PMID:
21523447
13.

[New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].

Rubello D, Rufini V, De Carlo E, Martini C, Calcagni ML, Sicolo N, Troncone L, Casara D.

Minerva Endocrinol. 2003 Dec;28(4):259-96. Review. Italian.

PMID:
14752399
14.
15.

State of the art and future prospects in the management of neuroendocrine tumors.

Oberg K.

Q J Nucl Med. 2000 Mar;44(1):3-12. Review.

PMID:
10932597
16.

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U.

Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20. Review.

PMID:
25140861
17.

Pancreatic neuroendocrine neoplasms.

Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Review.

PMID:
23207615
18.

Chemotherapy for gastro-enteropancreatic endocrine tumours.

O'Toole D, Hentic O, Corcos O, Ruszniewski P.

Neuroendocrinology. 2004;80 Suppl 1:79-84. Review.

PMID:
15477723
19.

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R.

Ann Oncol. 2010 Sep;21(9):1794-803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5. Review.

PMID:
20139156
20.

Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.

Cives M, Strosberg J.

Curr Treat Options Oncol. 2017 Mar;18(3):14. doi: 10.1007/s11864-017-0461-5. Review.

PMID:
28286921

Supplemental Content

Support Center